[Complement system in status asthmatics--analysis of anti-complementary effects induced by methylprendisolone].
Complement system was investigated in 7 patients with status asthmatics treated with large doses of methylprednisolone (MPS). Complement hemolytic activities, complement protein profile, complement fragments and circulating immune complexes were measured before, 3 and 8 hours after and 14 days after MPS administration. MPS normalized C4 and C1INH activities 6 hours after administration. MPS also decreased ACH50 6 hours after administration and D activity 3 and 6 hours after, but these activities recovered to their previous normal range within 14 days. P and H were decreased at each measurement time, and C1s was transiently decreased 6 hours after MPS administration. Complement fragment iC3b was increased at each measurement time, but fragment Bb tended to be decreased 14 days after MPS administration. The increment of anaphylatoxin C3a recovered to normal 14 days after MPS administration. In vitro experiments, MPS inhibited D and C1s activation directly, and decreased the decay of B and C4. Inhibition of C1s might also increase C1INH activity clinically. These results clarified that the alternative complement pathway was activated, and suggested that the C1 bypass pathway might be also activated in status asthmatics. It was further considered that these anti-complementary effects induced by MPS, brought about an improvement in asthmatic symptoms. Studies to identify the complement activators continued, and circulating immune complexes may possibly be one of those agents activating complement cascade.
Onodera
H
H
First Department of Internal Medicine, Kyoto Prefectural University of Medicine.
Takemura
S
S
Kasamatsu
Y
Y
Nakanishi
S
S
Seto
N
N
Ichio
N
N
Nakahara
R
R
Doi
T
T
Okamoto
M
M
Yanagida
K
K
D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000378:metabolism; D003170:Complement Pathway, Alternative / Q000187:drug effects; D003171:Complement Pathway, Classical / Q000187:drug effects; D003165:Complement System Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D013224:Status Asthmaticus / Q000188:drug therapy / Q000276:immunology*
D000936:Antigen-Antibody Complex; D003165:Complement System Proteins; D008775:Methylprednisolone